Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for Hepatic IRI in Liver Transplantation
NCT05031026Phase 4Active, not recruiting
- Sponsor
- Assiut University
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dexmedetomidine in hepatic ischemia-reperfusion injury (HIRI) (3 arms), sponsored by Assiut University. Primary endpoint: Syndecan-1 level at 48 hours. Started Mar 2022; status: active, not recruiting.
02
Drugs
dexmedetomidine
03
Conditions
hepatic ischemia-reperfusion injury (HIRI)
Beyond the preview
Go deeper on NCT05031026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031026.